Research and Markets: Cancer Cachexia - Pipeline Review, H2 2013 Research Report

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/tk8ldq/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2013" report to their offering.

'Cancer Cachexia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia.

Scope

- A snapshot of the global therapeutic scenario for Cancer Cachexia.

- A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Key Topics Covered:

Introduction

Cancer Cachexia Overview

Therapeutics Development

Pipeline Products for Cancer Cachexia - Overview

Drug Profiles

enobosarm - Drug Profile

anamorelin hydrochloride - Drug Profile

Xilonix - Drug Profile

macimorelin acetate - Drug Profile

clazakizumab - Drug Profile

anamorelin hydrochloride - Drug Profile

(megestrol + formoterol) - Drug Profile

(etodolac + propranolol) - Drug Profile

OHR/AVR-118 - Drug Profile

MT-102 - Drug Profile

LY-2495655 - Drug Profile

bimagrumab - Drug Profile

IP-1510 - Drug Profile

IP-1510 - Drug Profile

dronabinol - Drug Profile

tertomotide - Drug Profile

Ghrelin Receptor Agonists - Drug Profile

Drug Targeting Vps34 - Drug Profile

L-379 - Drug Profile

Activin Type IIB Receptor Antagonist - Drug Profile

DCB-CA2 - Drug Profile

Drug For Cancer Cachexia - Drug Profile

Drug Targeting Glutaminase - Drug Profile

Drugs For Cancer Cachexia - Drug Profile

Featured News & Press Releases

Appendix

List of Tables

List of Figures

Companies Mentioned

Amgen Inc.

Eli Lilly and Company

Novartis AG

Aphios Corporation

GTx, Inc.

AEterna Zentaris Inc.

Helsinn Healthcare S.A.

Alder Biopharmaceuticals Inc.

Vicus Therapeutics, LLC

Ohr Pharmaceutical Inc.

KAEL-GemVax Co., Ltd.

XBiotech USA, Inc.

Acacia Pharma Ltd.

PsiOxus Therapeutics, Ltd.

Signablok, Inc

Myomics, Inc.

Sprint Bioscience AB

Itis Pharmaceuticals Pty Ltd

For more information visit http://www.researchandmarkets.com/research/tk8ldq/cancer_cachexia

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals